Dual blockade of anti-VEGF and anti-PD-L1 enhances tumor immune therapy by inhibiting tumor angiogenesis and promoting T cell activation, resulting in improved anti-tumor immune responses and enhanced tumor control. This evidence concerns the gene CD274 and neoplasm.